Publication: AOA-2 Derivatives as Outer Membrane Protein A Inhibitors for Treatment of Gram-Negative Bacilli Infections
dc.contributor.author | Ayerbe-Algaba, Rafael | |
dc.contributor.author | Bayó, Nuria | |
dc.contributor.author | Verdú, Ester | |
dc.contributor.author | Parra-Millán, Raquel | |
dc.contributor.author | Seco, Jesús | |
dc.contributor.author | Teixidó, Meritxell | |
dc.contributor.author | Pachón, Jerónimo | |
dc.contributor.author | Giralt, Ernest | |
dc.contributor.author | Smani, Younes | |
dc.contributor.authoraffiliation | [Ayerbe-Algaba,R; Parra-Millán,R; Smani,Y] Clinical Unit of Infectious Diseases, Microbiology and Preventive Medicine, University Hospital Virgen del Rocío, Seville, Spain. [Ayerbe-Algaba,R; Parra-Millán,R; Pachón,J; Smani,Y] Institute of Biomedicine of Seville (IBiS), University Hospital Virgen del Rocío/Spanish National Research Council (CSIC)/University of Seville, Seville, Spain. [Bayó,N; Verdú,E; Seco,J; Teixidó,M; Giralt,E] Institute for Research in Biomedicine (IRB Barcelona), Barcelona Institute for Science and Technology (BIST), Barcelona, Spain. [Pachón,J] Department of Medicine, University of Seville, Seville, Spain. [Giralt,E] Department of Inorganic and Organic Chemistry, University of Barcelona, Barcelona, Spain. | |
dc.contributor.funder | This study was supported by the Instituto de Salud Carlos III, Proyectos de Investigación en Salud (Grants PI15/01358, PI16/01378, and PI19/01453) and by Plan Nacional de I + D + i 2013–2016 and Instituto de Salud Carlos III, Subdirección General de Redes y Centros de Investigación Cooperativa, Ministerio de Ciencia, Inno-vación y Universidades, Spanish Network for Research in Infectious Diseases (REIPI RD16/0016/0009)—co-financed by the European Development Regional Fund “A way to achieve Europe,” Operative program Intelligent Growth 2014–2020. YS was supported by the Subprograma Miguel Servet Tipo I from the Ministerio de Economía y Competitividad of Spain (CP15/00132). | |
dc.date.accessioned | 2022-08-09T07:09:42Z | |
dc.date.available | 2022-08-09T07:09:42Z | |
dc.date.issued | 2021-02-12 | |
dc.description.abstract | Previously, we identified that a cyclic hexapeptide AOA-2 inhibited the interaction of Gram-negative bacilli (GNB) like Acinetobacter baumannii, Pseudomonas aeruginosa, and Escherichia coli to host cells thereby preventing the development of infection in vitro and in a murine sepsis peritoneal model. In this work, we aimed to evaluate in vitro a library of AOA-2 derivatives in order to improve the effect of AOA-2 against GNB infections. Ten AOA-2 derivatives were synthetized for the in vitro assays. Their toxicities to human lung epithelial cells (A549 cells) for 24 h were evaluated by determining the A549 cells viability using 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay. The effect of these peptide derivatives and AOA-2 at 250, 125, 62.5, and 31.25 μg/mL on the attachment of A. baumannii ATCC 17978, P. aeruginosa PAO1 and E. coli ATCC 25922 strains to A549 cells was characterized by adherence and viability assays. None of the 10 derivatives showed toxicity to A549 cells. RW01 and RW06 have reduced more the adherence of ATCC 17978, PAO1 and ATCC 2599 strains to A549 cells when compared with the original compound AOA-2. Moreover, both peptides have increased slightly the viability of infected A549 cells by PAO1 and ATCC 25922 than those observed with AOA-2. Finally, RW01 and RW06 have potentiated the activity of colistin against ATCC 17978 strain in the same level with AOA-2. The optimization program of AOA-2 has generated two derivatives (RW01 and RW06) with best effect against interaction of GNB with host cells, specifically against P. aeruginosa and E. coli. | es_ES |
dc.description.version | Yes | es_ES |
dc.identifier.citation | Ayerbe-Algaba R, Bayó N, Verdú E, Parra-Millán R, Seco J, Teixidó M, et al. AOA-2 Derivatives as Outer Membrane Protein A Inhibitors for Treatment of Gram-Negative Bacilli Infections. Front Microbiol. 2021 Feb 12;12:634323 | es_ES |
dc.identifier.doi | 10.3389/fmicb.2021.634323 | es_ES |
dc.identifier.essn | 1664-302X | |
dc.identifier.pmc | PMC7907166 | |
dc.identifier.pmid | 33643267 | es_ES |
dc.identifier.uri | http://hdl.handle.net/10668/3898 | |
dc.journal.title | Frontiers in Microbiology | |
dc.language.iso | en | |
dc.page.number | 9 p. | |
dc.provenance | Realizada la curación de contenido 13/03/2025 | |
dc.publisher | Frontiers | es_ES |
dc.relation.publisherversion | https://www.frontiersin.org/articles/10.3389/fmicb.2021.634323/full | es_ES |
dc.rights | Atribución 4.0 Internacional | * |
dc.rights | Atribución 4.0 Internacional | * |
dc.rights.accessRights | open access | |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ | * |
dc.subject | AOA-2 derivatives | es_ES |
dc.subject | Outer membrane protein A | es_ES |
dc.subject | Inhibitor | es_ES |
dc.subject | Gram-negative bacilli | es_ES |
dc.subject | Peptides | es_ES |
dc.subject | Proteínas de la membrana bacteriana externa | es_ES |
dc.subject | Proteína estafilocócica A | es_ES |
dc.subject | Infecciones por bacterias gramnegativas | es_ES |
dc.subject | Péptidos | es_ES |
dc.subject | Infecciones | es_ES |
dc.subject | Ácido aminooxiacético | es_ES |
dc.subject.mesh | Medical Subject Headings::Organisms::Eukaryota::Animals::Chordata::Vertebrates::Mammals::Primates::Haplorhini::Catarrhini::Hominidae::Humans | es_ES |
dc.subject.mesh | Medical Subject Headings::Organisms::Eukaryota::Animals::Chordata::Vertebrates::Mammals::Rodentia::Muridae::Murinae::Mice | es_ES |
dc.subject.mesh | Medical Subject Headings::Organisms::Bacteria::Gram-Negative Bacteria::Gram-Negative Aerobic Bacteria::Gram-Negative Aerobic Rods and Cocci::Moraxellaceae::Acinetobacter::Acinetobacter baumannii | es_ES |
dc.subject.mesh | Medical Subject Headings::Organisms::Bacteria::Gram-Negative Bacteria::Gram-Negative Aerobic Bacteria::Gram-Negative Aerobic Rods and Cocci::Pseudomonadaceae::Pseudomonas::Pseudomonas aeruginosa | es_ES |
dc.subject.mesh | Medical Subject Headings::Chemicals and Drugs::Amino Acids, Peptides, and Proteins::Peptides::Peptides, Cyclic::Polymyxins::Colistin | es_ES |
dc.subject.mesh | Medical Subject Headings::Organisms::Bacteria::Proteobacteria::Gammaproteobacteria::Enterobacteriaceae::Escherichia::Escherichia coli | es_ES |
dc.subject.mesh | Medical Subject Headings::Chemicals and Drugs::Inorganic Chemicals::Bromine Compounds::Hydrobromic Acid::Bromides | es_ES |
dc.subject.mesh | Medical Subject Headings::Diseases::Bacterial Infections and Mycoses::Infection::Sepsis | es_ES |
dc.subject.mesh | Medical Subject Headings::Anatomy::Respiratory System::Lung | es_ES |
dc.subject.mesh | Medical Subject Headings::Chemicals and Drugs::Organic Chemicals::Amines::Hydroxylamines::Aminooxyacetic Acid | es_ES |
dc.title | AOA-2 Derivatives as Outer Membrane Protein A Inhibitors for Treatment of Gram-Negative Bacilli Infections | es_ES |
dc.type | research article | |
dc.type.hasVersion | VoR | |
dspace.entity.type | Publication |
Files
Original bundle
1 - 5 of 6
Loading...
- Name:
- AyerbeAlgaba_AOA2.pdf
- Size:
- 1020.39 KB
- Format:
- Adobe Portable Document Format
- Description:
- Artículo original
Loading...
- Name:
- AyerbeAlgaba_AOA2_MaterialSuplementario1.PDF
- Size:
- 592.58 KB
- Format:
- Adobe Portable Document Format
- Description:
- Material suplementario
Loading...
- Name:
- AyerbeAlgaba_AOA2_MaterialSuplementario2.PDF
- Size:
- 223.1 KB
- Format:
- Adobe Portable Document Format
- Description:
- Material suplementario
Loading...
- Name:
- AyerbeAlgaba_AOA2_MaterialSuplementario3.PDF
- Size:
- 225.61 KB
- Format:
- Adobe Portable Document Format
- Description:
- Material suplementario
Loading...
- Name:
- AyerbeAlgaba_AOA2_MaterialSuplementario4.PDF
- Size:
- 221.48 KB
- Format:
- Adobe Portable Document Format
- Description:
- Material suplementario